Literature DB >> 33221947

Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Possible Prognostic Markers for Patients Undergoing Resection of Adrenocortical Carcinoma.

Mechteld C de Jong1, Radu Mihai2, Shahab Khan2.   

Abstract

AIM: Adrenocortical cancer (ACC) is a rare disease with a poor outcome, and robust prognostic factors remain unclear. High neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as markers of host inflammation have been found to be associated with decreased long-term outcomes in several tumour types, but have been scarcely analysed in ACC.
METHODS: Patients who underwent resection of their ACC between 2000 and 2020 were identified; therapeutic, operative and outcome data were analysed. Pre-operative NLR and PLR were calculated by division of neutrophils and platelets by lymphocytes measured in peripheral blood.
RESULTS: Fifty-seven patients (30F:27 M) with an overall median age of 53 years [range: 18-86] presented with tumours of median size 11.5 cm [range: 3.0-22.0], of whom 26 (46%) were hormonally active. Majority of patients underwent an open resection (n = 48; 84%); more than half (n = 30; 53%) underwent multi-organ excision. Median NLR was 4.63 and median PLR was 186.21; these values were used for median split analyses (low vs. high). There were no differences with regard to age, sex or tumour characteristics and peri-operative data between the two groups (all p > 0.05). Overall, median recurrence-free survival (RFS) was 26 months (3-year: 45%) on Kaplan-Meier analysis. On univariate analyses, a high NLR did not influence RFS [HR = 1.57 (95%-CI: 0.73-2.38); p = 0.25], but patients with a high PLR had an increased risk of developing recurrence [HR = 2.39 (95%-CI: 1.08-5.31); p = 0.03]. The median overall survival (OS) was 33 months (3 years: 79%) on Kaplan-Meier analysis. Both a high NLR [HR = 2.24 (95%-CI: 1.07-4.70); p = 0.03] and a high PLR [HR = 4.02 (95%-CI: 1.80-8.98); p = 0.001] were strongly associated with a shorter OS on unadjusted analyses.
CONCLUSION: Elevated pre-operative NLR and PLR are associated with shorter OS, while higher PLR was also associated with a shorter RFS for patients undergoing curative intent resection of ACC.

Entities:  

Mesh:

Year:  2020        PMID: 33221947     DOI: 10.1007/s00268-020-05868-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  45 in total

Review 1.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

2.  Pathologic features of prognostic significance in adrenocortical carcinoma.

Authors:  L M Weiss; L J Medeiros; A L Vickery
Journal:  Am J Surg Pathol       Date:  1989-03       Impact factor: 6.394

3.  Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.

Authors:  R Libé; I Borget; C L Ronchi; B Zaggia; M Kroiss; T Kerkhofs; J Bertherat; M Volante; M Quinkler; O Chabre; M Bala; A Tabarin; F Beuschlein; D Vezzosi; T Deutschbein; F Borson-Chazot; I Hermsen; A Stell; C Fottner; S Leboulleux; S Hahner; M Mannelli; A Berruti; H Haak; M Terzolo; M Fassnacht; E Baudin
Journal:  Ann Oncol       Date:  2015-10       Impact factor: 32.976

Review 4.  Adrenocortical carcinoma: a clinician's update.

Authors:  Martin Fassnacht; Rossella Libé; Matthias Kroiss; Bruno Allolio
Journal:  Nat Rev Endocrinol       Date:  2011-03-08       Impact factor: 43.330

5.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

Authors:  Gwenaelle Abiven; Joel Coste; Lionel Groussin; Philippe Anract; Frédérique Tissier; Paul Legmann; Bertrand Dousset; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2006-05-02       Impact factor: 5.958

Review 6.  New perspectives for mitotane treatment of adrenocortical carcinoma.

Authors:  S Puglisi; A Calabrese; V Basile; A Pia; G Reimondo; P Perotti; M Terzolo
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2020-03-05       Impact factor: 4.690

Review 7.  Clinical management of adrenocortical carcinoma.

Authors:  Martin Fassnacht; Bruno Allolio
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-04       Impact factor: 4.690

8.  Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.

Authors:  Alfredo Berruti; Martin Fassnacht; Harm Haak; Tobias Else; Eric Baudin; Paola Sperone; Matthias Kroiss; Thomas Kerkhofs; Andrew R Williams; Arianna Ardito; Sophie Leboulleux; Marco Volante; Timo Deutschbein; Richards Feelders; Cristina Ronchi; Salvatore Grisanti; Hans Gelderblom; Francesco Porpiglia; Mauro Papotti; Gary D Hammer; Bruno Allolio; Massimo Terzolo
Journal:  Eur Urol       Date:  2013-11-14       Impact factor: 20.096

9.  Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.

Authors:  Montserrat Ayala-Ramirez; Sina Jasim; Lei Feng; Shamim Ejaz; Ferhat Deniz; Naifa Busaidy; Steven G Waguespack; Aung Naing; Kanishka Sircar; Christopher G Wood; Lance Pagliaro; Camilo Jimenez; Rena Vassilopoulou-Sellin; Mouhammed Amir Habra
Journal:  Eur J Endocrinol       Date:  2013-10-23       Impact factor: 6.664

10.  Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.

Authors:  Martin Fassnacht; Sarah Johanssen; Marcus Quinkler; Peter Bucsky; Holger S Willenberg; Felix Beuschlein; Massimo Terzolo; Hans-Helge Mueller; Stefanie Hahner; Bruno Allolio
Journal:  Cancer       Date:  2009-01-15       Impact factor: 6.860

View more
  3 in total

1.  Study on the Clinical Implications of NLR and PLR for Diagnosing Frailty in Maintenance Hemodialysis Patients and Their Correlations with Patient Prognosis.

Authors:  Jun Wang; Lijuan Huang; Meichang Xu; Lei Yang; Xu Deng; Bei Li
Journal:  J Healthc Eng       Date:  2022-01-12       Impact factor: 2.682

2.  Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors.

Authors:  Tae Hui Yun; Yoon Young Jeong; Sun Jae Lee; Youn Seok Choi; Jung Min Ryu
Journal:  J Clin Med       Date:  2022-03-01       Impact factor: 4.241

Review 3.  Tumor-Mediated Neutrophil Polarization and Therapeutic Implications.

Authors:  Sofia Raftopoulou; Paulina Valadez-Cosmes; Zala Nikita Mihalic; Rudolf Schicho; Julia Kargl
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.